Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma

Cancer Research

Volumn 66, Issue 13, 2006, Pages 6589-6597

  Vega, Francisco ^a   Medeiros, L Jeffrey ^a   Leventaki, Vasiliki ^a   Atwell, Coralyn ^a   Cho Vega, Jeong Hee ^a   Tian, Ling ^a   Claret, Francois Xavier ^a   Rassidakis, George Z ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; FLICE INHIBITORY PROTEIN; INITIATION FACTOR 4E BINDING PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHOPROTEIN; PROTEIN BCL 2; PROTEIN MCL 1; PROTEIN S6;

ADENOVIRUS; ANAPLASTIC CARCINOMA; APOPTOSIS; ARTICLE; CANCER SURVIVAL; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL LINE; CELL SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; DOWNSTREAM PROCESSING; HUMAN; HUMAN CELL; LARGE CELL LYMPHOMA; MYRISTYLATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR CELL;

1-PHOSPHATIDYLINOSITOL 3-KINASE; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; CHROMONES; DOWN-REGULATION; ENZYME ACTIVATION; HUMANS; LYMPHOMA, LARGE-CELL; MORPHOLINES; PHOSPHORYLATION; PROTEIN KINASES; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SIROLIMUS; TRANSFECTION;

EID: 33746118057     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-3018     Document Type: Article

References (46)

1. Delsol G, Ralfkiaer E, Stein H, Wright D, Jaffe ES. Anaplastic large cell lymphoma. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. World Health Organization classification of tumours. Pathology and genetics of tumors of haematopoietic and lymphoid tissues. Lyon (France): IABC Press; 2001. p.230-5.
2. Duyster J, Bai RY, Morris SW. Translocations involving anaplastic lymphoma kinase (ALK). Oncogene 2001;20:5623-37.
3. Morris SW, Kirstein MN, Valentine MB, et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 1994;263:1281-4.
4. Bai RY, Ouyang T, Miething C, Morris SW, Peschel C, Duyster J. Nucleophosmin-anaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3-kinase/Akt antiapoptotic signaling pathway. Blood 2000;96:4319-27.
5. Slupianek A, Nieborowska-Skorska M, Hoser G, et al. Role of phosphatidylinositol 3-kinase-Akt pathway in nucleophosmin/anaplastic lymphoma kinase-mediated lymphomagenesis. Cancer Res 2001;61:2194-9.
6. Peng XD, Xu PZ, Chen ML, et al. Dwarfism, impaired skin development, skeletal muscle atrophy, delayed bone development, and impeded adipogenesis in mice lacking Akt1 and Akt2. Genes Dev 2003;17:1352-65.
7. Hara K, Maruki Y, Long X, et al. Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell 2002;110:177-89.
8. Loewith R, Jacinto E, Wullschleger S, et al. Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol Cell 2002;10:457-68.
9. Pullen N, Thomas G. The modular phosphorylation and activation of p70s6k. FEBS Lett 1997;410:78-82.
10. Burnett PE, Barrow RK, Cohen NA, Snyder SH, Sabatini DM. RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1. Proc Natl Acad Sci U S A 1998;95:1432-7.
11. Schmelzle T, Hall MN. TOR, a central controller of cell growth. Cell 2000;103:253-62.
12. Sonenberg N, Gingras AC. The mRNA 5′ cap-binding protein eIF4E and control of cell growth. Curr Opin Cell Biol 1998;10:268-75.
13. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex Science 2005;307:1098-101.
14. Douros J, Suffness M. New antitumor substances of natural origin. Cancer Treat Rev 1981;8:63-87.
15. Eng CP, Sehgal SN, Vezina C. Activity of rapamycin (AY-22,989) against transplanted tumors. J Antibiot (Tokyo) 1984;37:1231-7.
16. Witzig TE, Geyer SM, Ghobrial I, et al. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol 2005;23:5347-56.
17. Brown VI, Fang J, Alcorn K, et al. Rapamycin is active against B-precursor leukemia in vitro and in vivo, an effect that is modulated by IL-7-mediated signaling. Proc Natl Acad Sci U S A 2003;100:15113-8.
18. Kim DH, Sarbassov DD, Ali SM, et al. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 2002;110:163-75.
19. Oshiro N, Yoshino K, Hidayat S, et al. Dissociation of raptor from mTOR is a mechanism of rapamycin-induced inhibition of mTOR function. Genes Cells 2004;9:359-66.
20. Kip1 levels and induces cell cycle arrest in anaplastic large cell lymphoma. Blood 2005;105:827-9.
21. Rassidakis GZ, Claret FX Lai R, et al. Expression of p27(Kip1) and c-Jun activation binding protein 1 are inversely correlated in systemic anaplastic large cell lymphoma. Clin Cancer Res 2003;9:1121-8.
22. Rassidakis GZ, Jones D, Thomaides A, et al. Apoptotic rate in peripheral T-cell lymphomas. A study using a tissue microarray with validation on full tissue sections. Am J Clin Pathol 2002;118:328-34.
23. Fujio Y, Guo K, Mano T, Mitsuuchi Y, Testa JR, Walsh K. Cell cycle withdrawal promotes myogenic induction of Akt, a positive modulator of myocyte survival. Mol Cell Biol 1999;19:5073-82.
24. Brown EJ, Beal PA, Keith CT, Chen J, Shin TB, Schreiber SL. Control of p70S6 kinase by kinase activity of FRAP in vivo. Nature 1995;377:441-6.
25. Bjornsti MA, Houghton PJ. The TOR pathway: a target for cancer therapy. Nat Rev Cancer 2004;4:335-48.
26. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2002;2:439-501.
27. Sekulic A, Hudson CC, Homme JL, et al. A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells. Cancer Res 2000;60:3504-13.
28. 2448 phosphorylation in the mammalian target of rapamycin by insulin and skeletal muscle load. J Biol Chem 2002;277:17657-62.
29. Harris TE, Lawrence JC, Jr. TOR signaling. Sci STKE 2003;2003:rel5.
30. Pyronnet S, Sonenberg N. Cell-cycle-dependent translational control. Curr Opin Genet Dev 2001;11:13-8.
31. Hammond ML, Bowman LH. Insulin stimulates the translation of ribosomal proteins and the transcription of rDNA in mouse myoblasts. J Biol Chem 1988;263:17785-91.
32. Harada H, Andersen JS, Mann M, Terada N, Korsmeyer SJ. p70S6 kinase signals cell survival as well as growth, inactivating the pro-apoptotic molecule BAD. Proc Natl Acad Sci U S A 2001;98:9666-70.
33. Shima H, Pende M, Chen Y, Fumagalli S, Thomas G, Kozma SC. Disruption of the p70(s6k)/p85(s61c) gene reveals a small mouse phenotype and a new functional S6 kinase. EMBO J 1998;17:6649-59.
34. Meyuhas O. Synthesis of the translational apparatus is regulated at the translational level. Eur J Biochem 2000;267;6321-30.
35. Sahin F, Kannangai R, Adegbola O, Wang J, Su G, Torbenson M. mTOR and p70 S6 kinase expression in primary liver neoplasms. Clin Cancer Res 2004;10:8421-5.
36. Kim JE, Chen J. Cytoplasmic-nuclear shuttling of FKBP12-rapamycin- associated protein is involved in rapamycin-sensitive signaling and translation initiation. Proc Natl Acad Sci U S A 2000;97:14340-5.
37. Wendel HG, De Stanchina E, Fridman JS, et al. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 2004;428:332-7.
38. Lazaris-Karatzas A, Smith MH, Frederickson RM, et al. Ras mediates translation initiation factor 4E-induced malignant transformation. Genes Dev 1992;6:1631-42.
39. Wang S, Rosenwald IB, Hutzler MJ, et al. Expression of the eukaryotic translation initiation factors 4E and 2α in non-Hodgkin's lymphomas. Am J Pathol 1999;155:247-55.
40. Jones RM, Branda J, Johnston KA, et al. An essential E box in the promoter of the gene encoding the mRNA cap-binding protein (eukaryotic initiation factor 4E) is a target for activation by c-myc. Mol Cell Biol 1996;16:4754-64.
41. Schalm SS, Blenis J. Identification of a conserved motif required for mTOR signaling. Curr Biol 2002;12:632-9.
42. Schalm SS, Fingar DC, Sabatini DM, Blenis J. TOS motif-mediated raptor binding regulates 4E-BP1 multi-site phosphorylation and function. Curr Biol 2003;13:797-806.
43. Chiang GG, Abraham RT. Phosphorylation of mammalian target of rapamycin (mTOR) at Ser-2448 is mediated by p70S6 kinase. J Biol Chem 2005;280:25485-90.
44. Holz MK, Blenis J. Identification of S6K1 as a novel mTOR-phosphorylating kinase. J Biol Chem 2005;280:26089-93.
45. Gera JF, Mellinghoff IK, Shi Y, et al. AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression. J Biol Chem 2004;279:2737-46.
46. Huang S, Liu LN, Hosoi H, Dilling MB, Shikata T, Houghton PJ. p53/p21(CIP1) cooperate in enforcing rapamycin-induced G(1) arrest and determine the cellular response to rapamycin. Cancer Res 2001;61:3373-81.